Ritu Lal
Company: Gen1E Lifesciences
Job title: Chief Executive Officer
Seminars:
Unlocking Multiple Mechanisms of Action Using a Unique AI/ML Platform with Novel Immunomodulators for ARDS Patients 8:45 am
Highlighting the lead compound is Phase 2 ready for ARDS patients (including COVID-ARDS) having completed Phase 1 Using the unique AI/ML platform to develop 21 next generation p38 alpha/MK2 novel immunomodulatorsRead more
day: Day Two
Panel Discussion: Determining the Extent the Understandings Gained from Covid-19 ARDS Can Be Translated Into ARDS 2:55 pm
day: Day Two
Unlocking Multiple Mechanisms of Action Using a Unique AI/ML Platform with Novel Immunomodulators for ARDS Patients 8:50 am
Highlighting the lead compound is Phase 2 ready for ARDS patients (including COVID-ARDS) having completed Phase 1 Using the unique AI/ML platform to develop 21 next generation p38 alpha/MK2 novel immunomodulatorsRead more